Welcome to our dedicated page for HEARTFLOW SEC filings (Ticker: HTFL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Heartflow, Inc. filings document a Nasdaq-listed Delaware medical technology company focused on AI software for coronary artery disease. Its recent 8-K reports furnish operating results, investor presentations and Regulation FD disclosures, while also recording capital-structure events tied to its completed initial public offering and repayment and termination of a credit agreement.
The company’s proxy materials cover annual meeting matters, director elections, auditor ratification and stockholder voting mechanics. As an emerging growth company, Heartflow’s filings also identify governance, exchange listing, financial reporting and public-company status disclosure areas relevant to a commercial-stage medical technology issuer.
Heartflow, Inc. director William C. Weldon exercised stock options to acquire 51,369 shares of Common Stock on 2026-07-08 through three derivative exercises. Each exercise covered 17,123 underlying shares at an exercise price of 8.3300 per share. Following these transactions, he holds 209,685 shares of Common Stock directly, with the exercised stock options now fully used.
HTFL submits a Rule 144 notice to sell 22,562 common shares related to a stock option exercise dated 06/25/2024.
The filing lists recent sales by John C. M. Farquhar: 04/10/2026 22,562 shares for $602,856.64; 05/11/2026 22,562 shares for $657,005.44; 06/10/2026 22,562 shares for $643,017.00; and 06/24/2026 38,900 shares for $1,361,500.00.
Heartflow, Inc. Chief Executive Officer John C.M. Farquhar reported an open-market sale of common stock. On June 24, 2026, he sold 38,900 shares at $35.00 per share in a transaction executed under a Rule 10b5-1 trading plan adopted on September 12, 2025.
Following the sale, Farquhar directly held 457,935 shares of Heartflow common stock. The sale amounts to roughly 8% of his post-transaction holdings, suggesting a moderate, pre-planned reduction rather than a large change in his overall equity position.
HTFL submitted a Form 144 notice to sell 38,900 shares of Common Stock, listed as securities issued upon a stock option exercise on 06/25/2024. The filing lists brokerage handling by Fidelity Brokerage Services LLC and indicates cash proceeds as the sale method. The excerpt also shows recent open-market dispositions by John C. M. Farquhar of 22,562 shares on 04/10/2026, 22,562 shares on 05/11/2026, and 22,562 shares on 06/10/2026, with reported gross amounts for each sale.
Heartflow, Inc. director William C. Weldon received a new stock option grant. The award covers 16,075 stock options for Heartflow common stock at an exercise price of $32.05 per share, giving him the right to buy shares at that price in the future.
The option vests in full on the earlier of the day prior to Heartflow's 2027 annual meeting of shareholders or the first anniversary of the grant date, subject to his continued service. After this grant, he holds 16,075 options directly, and the option is scheduled to expire on June 16, 2036.
Heartflow, Inc. director Timothy C. Barabe received a grant of stock options as part of his compensation. He was awarded options to purchase 16,075 shares of Heartflow common stock at an exercise price of $32.05 per share, expiring on June 16, 2036. Following this grant, he holds 16,075 stock options directly. According to the terms, the option will vest in full on the earlier of the day prior to Heartflow's 2027 annual meeting of shareholders or the first anniversary of the grant date, subject to his continued service.
Heartflow, Inc. reported that director Julie A. Cullivan received a grant of stock options covering 16,075 shares of common stock. The options have an exercise price of $32.05 per share and expire on June 16, 2036.
According to the terms, the option will vest in full on the earlier of the day prior to Heartflow's annual meeting of shareholders in 2027 or the first anniversary of the grant date, subject to her continued service through that date. This filing reflects a compensation-related award, with no share sales reported.
Heartflow, Inc. director Jeffrey C. Lightcap received a grant of stock options covering 16,075 shares of common stock. The options have an exercise price of $32.05 per share and expire on June 16, 2036.
According to the grant terms, the option will vest in full on the earlier of the day prior to Heartflow’s annual meeting of shareholders in 2027 and the first anniversary of the grant date, subject to Mr. Lightcap’s continued service through that date. Following this grant, he holds options for 16,075 underlying shares directly.
Heartflow, Inc. director Riley Wayne Joseph reported receiving a stock option grant as part of his compensation. The award covers 16,075 shares of common stock at an exercise price of $32.05 per share, with the option expiring on June 16, 2036.
The filing shows this is a grant/award acquisition rather than an open-market trade. According to the terms, the option will vest in full on the earlier of the day prior to Heartflow's 2027 annual shareholder meeting or the first anniversary of the grant date, subject to his continued service.
Heartflow, Inc. director Casey M. Tansey reported a grant of stock options. On the reported date, Tansey received options covering 16,075 shares of Common Stock at an exercise price of $32.05 per share. Following this grant, Tansey held 16,075 derivative securities directly.
The option will vest in full on the earlier of the day prior to Heartflow's 2027 annual meeting of shareholders and the first anniversary of the grant date, subject to continued service through that date. The options are scheduled to expire on June 16, 2036 if not exercised.